Tuberculosis versus immune-related bronchiolitis under immune checkpoint inhibitor - a diagnostic challenge.

Acta Clin BelgApr 30, 2026 (epub)

Clara Moreno, Nieves Martinez Chanza, Lou Gonzalez Garcia et al.

✦ AI-curated · Sources linked

Case in brief

A 53-year-old man with metastatic clear-cell renal cell carcinoma developed respiratory symptoms after receiving immune checkpoint inhibitors. Imaging revealed centrilobular nodules, and QuantiFERON testing was positive. Bronchoalveolar lavage showed lymphocyte predominance and non-caseating granulomas. Despite negative PCR for tuberculosis, empirical anti-TB therapy was initiated due to the diagnostic challenge. The patient improved after adjusting the treatment regimen.

Diagnostic / clinical pearl

Clinicians should be aware of the diagnostic overlap between immune-related bronchiolitis and tuberculosis in patients receiving immune checkpoint inhibitors, particularly in endemic regions.

Why it matters

This case highlights the importance of pre-treatment latent TB screening and the need for a multidisciplinary approach to manage potential infections while continuing cancer therapy.

Source

Published in Acta Clin Belg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.